An allergic conjunctivitis medicine developed by Aldeyra Therapeutics (Nasdaq: ALDX), reproxalap, has generated positive Phase III data in the INVIGORATE-2 trial.
Shares in the company were lifted on Thursday, although gains have now fallen away.
Aldeyra, a Massachusetts-based firm working on innovative therapies for immune-mediated diseases, hopes the drug will help people who have a poor response to over-the-counter options.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze